NASDAQ: CRDL - Cardiol Therapeutics Inc.

半年間の収益性: +5.35%
セクタ: Healthcare

プロモーションスケジュール Cardiol Therapeutics Inc.


会社について

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx for patients hospitalized with COVID-19, as well as for the treatment of recurrent pericarditis and acute myocarditis.

さらに詳しく
The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.

Выручка 7.9E-5
EBITDA -0.0134
Число акций ао 0.06446 млрд
P/S 1350.96
P/BV 8.25
Цена ао 1.95
EV/EBITDA -8.51
ISIN CA14161Y2006
Сайт https://www.cardiolrx.com
Валюта usd
IPO date 2019-01-15
Sector Health Care
Industry Biotechnology
Валюта отчета cad
1日あたりの価格変動: +1.03% (1.95)
週ごとの価格変動: -4.83% (2.07)
月ごとの料金変更: +7.65% (1.83)
3ヶ月間の価格変動: +3.68% (1.9)
半年間の価格変動: +5.35% (1.87)
年間の価格変動: +145.94% (0.801)
3年間の価格推移: -58.96% (4.8)
5年間の価格推移: -38.38% (3.197)
年初からの価格変動: +157.52% (0.765)

過小評価

名前 意味 学年
P/S 0 0
P/BV 2.51 6
P/E 0 0
EV/EBITDA -1.23 0
合計: 3.25

効率

名前 意味 学年
ROA, % -76.64 0
ROE, % -99.58 0
合計: 0

配当金

名前 意味 学年
Div yield, % 0 0
DSI 0 0
合計: 0

義務

名前 意味 学年
Debt/EBITDA -0.0059 10
合計: 9.6

成長の衝動

名前 意味 学年
収益性 Revenue, % 0 0
収益性 Ebitda, % 119.89 10
収益性 EPS, % -0.0244 0
合計: 6

ETF 共有, % 年間の利益率, % 配当金, %
AdvisorShares Pure Cannabis ETF 6.51027 -3.728813559322 1.68573



スーパーバイザー 役職 支払い 生年
Mr. David G. Elsley MBA President, CEO & Director 550.14k
Mr. Christopher J. Waddick C.A., C.M.A., CPA, CMA, MBA CFO, Corporate Secretary & Director 216.79k
Mr. Bernard Lim B.Sc. Chief Operating Officer 379.39k
Dr. Andrew Warwick Hamer M.D. Chief Medical Officer & Head of Research & Development 549.01k 1962 (62 年)
Trevor Burns Investor Relations N/A
Mr. John A. Geddes BSCPT, MBA Vice President of Corporate Development

住所: Canada, Oakville, 2265 Upper Middle Road East - Googleマップで開く, Yandexマップを開く
Webサイト: https://www.cardiolrx.com